P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.

ABSTRACT:

Objective

To assess the risks and benefits of P2Y₁₂ inhibitor monotherapy compared with dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' characteristics.

Design

Individual patient level meta-analysis of randomised controlled trials.

Data sources

Searches were conducted in Ovid Medline, Embase, and three websites (www.tctmd.com, www.escardio.org, www.acc.org/cardiosourceplus) from inception to 16 July 2020. The primary authors provided individual participant data.

Eligibility criteria

Randomised controlled trials comparing effects of oral P2Y₁₂ monotherapy and DAPT on centrally adjudicated endpoints after coronary revascularisation in patients without an indication for oral anticoagulation.

Main o

SUBMITTER: Valgimigli M 

PROVIDER: S-EPMC8207247 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature